1. Home
  2. EVTL vs JSPR Comparison

EVTL vs JSPR Comparison

Compare EVTL & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertical Aerospace Ltd.

EVTL

Vertical Aerospace Ltd.

HOLD

Current Price

$1.65

Market Cap

338.7M

Sector

Industrials

ML Signal

HOLD

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.35

Market Cap

14.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVTL
JSPR
Founded
2016
2018
Country
United Kingdom
United States
Employees
454
22
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
338.7M
14.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EVTL
JSPR
Price
$1.65
$0.35
Analyst Decision
Strong Buy
Buy
Analyst Count
7
11
Target Price
$12.70
$15.50
AVG Volume (30 Days)
2.4M
713.1K
Earning Date
03-24-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.69
$0.42
52 Week High
$7.60
$7.19

Technical Indicators

Market Signals
Indicator
EVTL
JSPR
Relative Strength Index (RSI) 25.38 25.74
Support Level N/A N/A
Resistance Level $2.89 $1.02
Average True Range (ATR) 0.15 0.06
MACD -0.05 0.01
Stochastic Oscillator 4.95 3.77

Price Performance

Historical Comparison
EVTL
JSPR

About EVTL Vertical Aerospace Ltd.

Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: